Inequalities in diagnosis and registration of pediatric very rare tumors: a European study on pleuropulmonary blastoma
Jazyk angličtina Země Německo Médium print-electronic
Typ dokumentu časopisecké články
Grantová podpora
777336 PARTNER
European Commission
PubMed
31901982
DOI
10.1007/s00431-019-03566-7
PII: 10.1007/s00431-019-03566-7
Knihovny.cz E-zdroje
- Klíčová slova
- Cancer registry, Childhood cancer, Pleuropulmonary blastoma, Rare tumors,
- MeSH
- dítě MeSH
- incidence MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- nádory plic diagnóza epidemiologie MeSH
- novorozenec MeSH
- plicní blastom diagnóza epidemiologie MeSH
- předškolní dítě MeSH
- průřezové studie MeSH
- registrace statistika a číselné údaje MeSH
- retrospektivní studie MeSH
- Check Tag
- dítě MeSH
- kojenec MeSH
- lidé MeSH
- mladiství MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Evropa epidemiologie MeSH
Very rare tumors (VRTs) account for up to 11% of childhood cancers. Dedicated national groups and registries only exist in some European countries. Pleuropulmonary blastoma (PPB) is a very rare intrathoracic pediatric tumor with a potentially severe prognosis. Due to its rarity, it sometimes goes unrecognized. We investigated PPB diagnostic capability and possible correlations between diagnostic performance and VRT-dedicated activities. The number of cases of PPB registered between 2000 and 2014 at pediatric oncology centers in Europe was compared with the number of expected cases. Data sources included VRT registries, population-based cancer registries, and hospital registries. Data were obtained for 25 countries, grouped into 4 geographical regions. The expected cases were 111, and the observed cases were 129. The observed-to-expected ratio was 1.86 for Northern Europe, 1.33 for Southern Europe, 1.22 for Central Europe, and 0.65 for Eastern Europe. More cases than expected were registered in all countries with an official VRT registry.Conclusion: The number of cases observed is consistent with expectations, but disparities exist across Europe. Difficulties in diagnosing PPB emerged in most Eastern countries. The incidence rate of PPB may be underestimated. The creation of VRT-dedicated groups and a European Registry for VRTs could help to reduce inequalities.What is Known:• Very rare pediatric tumors are often not recognized, despite representing almost 11% of childhood cancers .• Pleuropulmonary blastoma is a rare pediatric tumor with a poor prognosis.What is New:• The ability to diagnose and register pleuropulmonary blastoma varies in Europe.Registries dedicated to very rare pediatric tumors improve the diagnostic rates.• The incidence rate of pleuropulmonary blastoma may currently be underestimated.
Department of Pediatric Hematology and Oncology Children's Hospital Tuebingen Germany
Department of Pediatric Oncology Faculty of Medicine Masaryk University Brno Czech Republic
Pediatric Hematology and Oncology Unit Centro Hospitalar de Sao Joao Porto Portugal
Pediatric Hematology Oncology Immunology Unit Angers University Hospital Angers France
Pediatric Hematology Oncology Unit Kaplan Medical Center Rehovot Israel
Pediatric Oncology and Hematology Unit Cruces University Hospital Barakaldo Spain
Pediatric Oncology Unit Aglaia Kyriakou Children's Hospital Athens Greece
Pediatric Oncology Unit Fondazione IRCCS Istituto Nazionale Tumori Milan Italy
Pediatric Oncology Unit Princess Maxima Center for Pediatric Oncology Utrechtx Netherlands
SIREDO Oncology Center Institut Curie Université PSL Paris France
Zobrazit více v PubMed
Eur J Cancer. 2018 Jun;96:44-53 PubMed
Cancer. 1988 Oct 15;62(8):1516-26 PubMed
Eur J Cancer. 2019 Mar;110:120-126 PubMed
Eur J Cancer. 2014 Jan;50(1):178-84 PubMed
Bull Cancer. 2010 Sep;97(9):1041-5 PubMed
Lancet Oncol. 2017 Jun;18(6):719-731 PubMed
Eur J Cancer. 2011 Nov;47(17):2493-511 PubMed
Eur J Cancer. 2017 Sep;82:137-148 PubMed
Pediatr Blood Cancer. 2007 Mar;48(3):370-1 PubMed
J Surg Oncol. 2017 Feb;115(2):164-172 PubMed
Klin Padiatr. 2012 Oct;224(6):416-20 PubMed
Clin Cancer Res. 2018 May 15;24(10):2251-2261 PubMed
Pediatr Blood Cancer. 2014 Jul;61(7):1202-9 PubMed
Przegl Lek. 2004;61 Suppl 2:57-61 PubMed
Cancer. 2015 Jan 15;121(2):276-85 PubMed
Lancet Oncol. 2014 Jan;15(1):35-47 PubMed
Eur J Cancer. 2007 Mar;43(4):654-9 PubMed
Pediatr Blood Cancer. 2009 Aug;53(2):152-5 PubMed
J Pediatr Surg. 2016 Jan;51(1):33-7 PubMed